Meta-analysis of five RCTs (2380 women, FIGO stage III-IV ovarian cancer): neoadjuvant chemotherapy with interval surgery vs primary debulking showed no difference in OS (HR 1.00) or PFS (HR 1.03), with fewer grade ≥3 perioperative complications (RR 0.43).
Meta-analysisn = 2,380
Secchi et al. Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis